Fig. 3.

Strategies for IL-1 blockade with Kineret (Anakinra (Swedish Orphan Biovitrum AB, Sweden)). a Interleukin (IL)-1 binds to type 1 IL-1 receptor (IL-1R1) and to the adaptor protein, IL-1RAcP, in order to trigger signal transduction. b The recombinant human IL-1R1 antagonist, Anakinra, directly competes with IL-1 for binding to the IL-1R1, blocking the biological activity of IL-1. Bettiol A, Lopalco G, Emmi G, et al. Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases. Int J Mol Sci. 2019;20(8):1898. Published 2019 Apr 17. doi:10.3390/ijms20081898. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited